New advances in stem cell research: Practical implications for regenerative medicine

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 7-8, 2014, Pages 417-426

  Ratajczak, Mariusz Z ^a,b   Jadczyk, Tomasz ^c   Pȩdziwiatr, Daniel ^b   Wojakowski, Wojciech ^c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Embryonic stem cells; Induced pluripotent stem cells; Paracrine effects; Therapeutic cloning; Very small embryonic like stem cells

Indexed keywords

ADULT STEM CELL; CARDIOLOGY; CELL CLONING; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CLINICAL TRIAL (TOPIC); EMBRYONAL TISSUE; HUMAN; META ANALYSIS (TOPIC); MULTIPOTENT STEM CELL; NEUROLOGY; NONHUMAN; OPHTHALMOLOGY; PARACRINE SIGNALING; PLASTICITY; PLURIPOTENT STEM CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; REVIEW; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; THERAPY EFFECT; BIOLOGICAL THERAPY; EMBRYONIC STEM CELL; PROCEDURES;

CELL- AND TISSUE-BASED THERAPY; EMBRYONIC STEM CELLS; HUMANS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84906873756     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2355     Document Type: Review

References (67)

1. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013; 113: 810-834.
2. Doppler SA, Deutsch MA, Lange R, et al. Cardiac regeneration: current therapies-future concepts. J Thorac Dis. 2013; 5: 683-697.
3. Tibbetts MD, Samuel MA, Chang TS, et al. Stem cell therapy for retinal disease. Curr Opin Ophthalmol. 2012; 23: 226-234.
4. Trounson A, Thakar RG, Lomax G, et al. Clinical trials for stem cell therapies. BMC Med. 2011; 9: 52.
5. Martínez-Morales PL, Revilla A, Ocaña I, et al. Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev. 2013; 9: 685-699.
6. Salibian AA, Widgerow AD, Abrouk M, et al. Stem cells in plastic surgery: a review of current clinical and translational applications. Arch Plast Surg. 2013; 40: 666-675.
7. Botti C, Maione C, Coppola A, et al. Autologous bone marrow cell therapy for peripheral arterial disease. Stem Cells Cloning. 2012; 5: 5-14.
8. Salgado AJ, Oliveira JM, Martins A, et al. Tissue engineering and regenerative medicine: past, present, and future. Int Rev Neurobiol. 2013; 108: 1-33.
9. Ratajczak MZ, Shin DM, Schneider G, et al. Parental imprinting regulates insulin-like growth factor signaling: a Rosetta Stone for understanding the biology of pluripotent stem cells, aging and cancerogenesis. Leukemia. 2013; 27:773-779.
10. Ratajczak MZ, Zuba-Surma E, Kucia M, et al. Pluripotent and multipotent stem cells in adult tissues. Adv Med Sci. 2012; 57: 1-17.
11. Ratajczak MZ, Suszyńska M. [Quo vadis regenerative medicine?] Acta Haematol Pol. 2013; 44: 161-170. Polish.
12. Kramer AS, Harvey AR, Plant GW, et al. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury. Cell Transplant. 2013; 22: 571-617.
13. Hong EJ, Jeung EB. Assessment of developmental toxicants using human embryonic stem cells. Toxicol Res. 2013; 29: 221-227.
14. Cunningham JJ, Ulbright TM, Pera MF, et al. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol. 2012; 30: 849-857.
15. McHugh PR. Zygote and "clonote"-the ethical use of embryonic stem cells. N Engl J Med. 2004; 351: 209-211. (Pubitemid 38916037)
16. Bobbert M. Ethical questions concerning research on human embryos, embryonic stem cells and chimeras. Biotechnol J. 2006; 1: 1352-1369.
17. Obokata H, Wakayama T, Sasai Y, et al. Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature. 2014; 505: 641-647.
18. Ronen D, Benvenisty N. Genomic stability in reprogramming. Curr Opin Genet Dev. 2012; 22: 444-449.
19. Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474: 212-215.
20. Abad M, Mosteiro L, Pantoja C, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013; 502: 340-345.
21. Beltrami AP, Cesselli D, Bergamin N, et al. Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). Blood. 2007; 110: 3438-3446. (Pubitemid 350106340)
22. Anjos-Afonso F, Bonnet D. Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood. 2007; 109: 1298-1306. (Pubitemid 46220683)
23. Wakao S, Kitada M, Kuroda Y, et al. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci U S A. 2011; 108: 9875-9880.
24. Jiang Y, Vaessen B, Lenvik T, et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol. 2002; 30: 896-904. (Pubitemid 34845893)
25. Kögler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004; 200: 123-135. (Pubitemid 38982172)
26. D'Ippolito G, Diabira S, Howard GA, et al. Marrow-isolated adult multi-lineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci. 2004; 117: 2971-2981. (Pubitemid 39117672)
27. Vacanti MP, Roy A, Cortiella J, et al. Identification and initial characterization of spore-like cells in adult mammals. J Cell Biochem. 2001; 80: 455-460.
28. Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia. 2006; 20: 857-869.
29. Kucia M, Halasa M, Wysoczynski M, et al. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia. 2007; 21: 297-303. (Pubitemid 46158123)
30. Wojakowski W, Tendera M, Kucia M, et al. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J Am Coll Cardiol. 2009; 53: 1-9.
31. Paczkowska E, Kucia M, Koziarska D, et al. Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after stroke. Stroke. 2009; 40: 1237-1244.
32. Marlicz W, Zuba-Surma E, Kucia M, et al. Various types of stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients with Crohn's disease. Inflamm Bowel Dis. 2012; 18: 1711-1722.
33. Drukała J, Paczkowska E, Kucia M, et al. Stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripher-al blood in patients after skin burn injury. Stem Cell Rev. 2012; 8: 184-194.
34. Ratajczak MZ. Phenotypic and functional characterization of hematopoietic stem cells. Curr Opin Hematol. 2008; 15: 293-300.
35. Scott EW. Stem cell plasticity or fusion: two approaches to targeted cell therapy. Blood Cells Mol Dis. 2004; 32: 65-67. (Pubitemid 38147698)
36. Eisenberg LM, Eisenberg CA. Stem cell plasticity, cell fusion, and trans-differentiation. Birth Defects Res C Embryo Today. 2003; 69: 209-218. (Pubitemid 37238398)
37. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001; 97: 3075-3085.
38. Ratajczak J, Kucia M, Mierzejewska K, et al. Paracrine proangiopoietic effects of human umbilical cord blood-derived purified CD133+ cells-implications for stem cell therapies in regenerative medicine. Stem Cells Dev. 2013; 22: 422-430.
39. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006; 20: 847-856.
40. Ratajczak MZ, Kucia M, Jadczyk T, et al. Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? Leukemia. 2012; 26: 1166-1173.
41. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from hu-man adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011; 26: 1474-1483.
42. Aliotta JM, Sanchez-Guijo FM, Dooner GJ, et al. Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells. 2007; 25: 2245-2256. (Pubitemid 47480483)
43. Suszynska M, Zuba-Surma EK, Maj M, et al. The proper criteria for identification and sorting of very small embryonic-like stem cells, and some nomenclature issues. Stem Cells Dev. 2014; 23: 702-713.
44. Havens AM, Shiozawa Y, Jung Y, et al. Human very small embryonic-like cells generate skeletal structures, in vivo. Stem Cells Dev. 2013; 22: 622-630.
45. Kassmer SH, Jin H, Zhang PX, et al. Very small embryonic-like stem cells from the murine bone marrow differentiate into epithelial cells of the lung. Stem Cells. 2013; 31: 2759-2766.
46. Virant-Klun I, Zech N, Rozman P, et al. Putative stem cells with an embryonic character isolated from the ovarian surface epithelium of women with no naturally present follicles and oocytes. Differentiation. 2008; 76: 843-856.
47. Havens AM, Sun H, Shiozawa Y, et al. Human and murine very small embryonic-like cells represent multipotent tissue progenitors, in vitro and in vivo. Stem Cells Dev. 2014; 23: 689-701.
48. Parte S, Bhartiya D, Telang J, et al. Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary. Stem Cells Dev. 2011; 20: 1451-1464.
49. Coulombe KL, Bajpai VK, Andreadis ST, et al. Heart Regeneration with Engineered Myocardial Tissue. Annu Rev Biomed Eng. 2014 Apr 24. E-pub ahead of print.
50. Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J. 2011; 32: 1197-1206.
51. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008; 102: 1319-1330.
52. Tendera M, Wojakowski W, Ruzyłło W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009; 30: 1313-1321.
53. Houtgraaf JH, de Jong R, Kazemi K, et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res. 2013; 113: 153-166.
54. Delewi R, Hirsch A, Tijssen JG, et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J. 2014; 35: 989-998.
55. Nowbar AN, Mielewczik M, Karavassilis M, et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 2014; 348: g2688.
56. Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation. 2013; 128: S42-49.
57. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart fail-URE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61: 2329-2338.
58. van Ramshorst J, Rodrigo SF, Beeres SL, et al. Long term effects of intramyocardial bone marrow cell injection on anginal symptoms and quality of life in patients with chronic myocardial ischemia. Int J Cardiol. 2013; 168: 3031-3032.
59. Faravelli I, Riboldi G, Nizzardo M, et al. Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation. Cell Mol Life Sci. 2014. [Epub ahead of print].
60. Jarocha D, Milczarek O, Kawecki Z, et al. Preliminary study of autologous bone marrow nucleated cells transplantation in children with spinal cord injury. Stem Cells Transl Med. 2014; 3: 395-404.
61. Harrop JS, Hashimoto R, Norvell D, et al. Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review. J Neurosurg Spine. 2012; 17: 230-246.
62. Ramsden CM, Powner MB, Carr AJ, et al. Stem cells in retinal regeneration: past, present and future. Development. 2013; 140: 2576-2585.
63. Habich A, Jurga M, Markiewicz I, et al. Early appearance of stem/progenitor cells with neural-like characteristics in human cord blood mononuclear fraction cultured in vitro. Exp Hematol. 2006; 34: 914-925.
64. Ertl RP, Chen J, Astle CM, et al. Effects of dietary restriction on hematopoietic stem-cell aging are genetically regulated. Blood. 2008; 111: 1709-1716. (Pubitemid 351213463)
65. Park JH, Glass Z, Sayed K, et al. Calorie restriction alleviates the age-related decrease in neural progenitor cell division in the aging brain. Eur J Neurosci. 2013; 37: 1987-1993.
66. Cerletti M, Jang YC, Finley LW, et al. Short-term calorie restriction enhances skeletal muscle stem cell function. Cell Stem Cell. 2012; 10: 515-519.
67. Abbott A. Doubts over heart stem-cell therapy. Nature. 2014; 509: 15-16.